Group 1: Financial Performance - The company's budget for 2023 is projected at a revenue of 1.1 billion and a net profit of 36 million [5] - The net profit margin for the ophthalmology segment is expected to recover to 6%-8% for the full year of 2023 [3] - The company aims for a 48% increase in revenue compared to 2022 [5] Group 2: Market Strategy - The company focuses on regional scale development, targeting five major city clusters: Yangtze River Delta, Pearl River Delta, Beijing-Tianjin-Hebei, Jiaodong Peninsula, and Chengdu-Chongqing [2][3] - These five core city clusters account for one-third of China's population and 50% of its GDP, indicating a concentrated demand for ophthalmic medical services [2] - The company has established 14 specialized ophthalmology hospitals and 2 optometry clinics across major cities, maintaining a leading position in the private ophthalmology sector [6] Group 3: Business Expansion - The company is pursuing both organic growth and external expansion, with plans to acquire and inject profitable targets into the company [6][9] - Current successful hospitals generate annual revenues ranging from 150 million to 300 million [9] - The company has initiated external layouts, such as partnerships with Meiermu and Suzhou Ear, Nose, and Throat Hospital [2][9] Group 4: Service and Product Development - The company is enhancing its service offerings, with a focus on cataract surgery, which has seen a rise in high-end lens surgery from 50% in 2021 to 77% in Q1 2023 [3] - The proportion of refractive income has increased from approximately 25% in 2018 to 44% in 2022, while optometry income rose from 7% to 16% in the same period [3] - The company plans to develop a comprehensive approach to eye care, focusing on cataracts, refractive surgery, and optometry [3] Group 5: Operational Efficiency - The company is implementing measures to reduce sales and management expense ratios, which have already seen a decline in 2022 [5] - A focus on improving operational efficiency and resource allocation is underway, with the establishment of six business units to enhance management quality [5][6] - The company is exploring the integration of AI technologies, such as ChatGPT, to improve patient services and operational efficiency [3]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-045 光正眼科医院集团股份有限公司 关于参加 2023 年新疆辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，光正眼科医院集团股份有限公司（以下 简称"公司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年新疆辖区上市公司投资者网上集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）15:30-18:00。届时 公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ 特此公告。 光正眼科医院集团股份有限公司董事会 二〇二三年六月十三日 ...

光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 编号：2023-002 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称 通过网络方式参加公司 2022 年度业绩网上说明会的投资者 时间 2023 年 5 月 12 日（星期五）下午 15：00-17：00 地点 全景网 http://www.p5w.net/ 上市公司接待 人员姓名 公司董事长、总经理周永麟先生；独立董事郑石桥先生；董事、 副总经理王建民先生；董事、财务总监李俊英女士；董事会秘 书李薇女士； 投资者关系活 动主要内容介 绍 1.今年的还有业绩对赌协议吗？ 答：公司收购新视界眼科的业绩对赌期已结束，今年无业 绩对赌协议。 2.请问公司关于对新视界重大资产重组业绩补偿诉讼的进 展如何？ 答：您好！关于新视界重大资产重组业绩补偿诉讼案已于 2022 年 8 月 31 日一审判决，且判决结果已生效。详情请见公司 发布在指定媒体的公告（公告编号：2022-067、2022-069）。 根据本次判决结果，公司减少支付股权转让款合计 21,200 万 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 编号：2023-001 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 新闻发布会 □路演活动 活动类别 □现场参观 其他（ 海通证券、中信建投、西南证券、华安证券举办的电 话会 ） | --- | |---------------------------------------------------------------| | 海通证券&海通国际：梁广楷、陈铭；中信建投：贺菊颖、王在存、 | | 吴严、正涛；西南证券：杜向阳、王钰畅；华安证券：谭国超、 | | 陈珈蔚；安信证券：贺鑫；上海证券：徐昕；东北证券：古翰羲； | | 东吴证券：冉胜男、苏丰；中金公司：张一弛；中泰：孙宇瑶； | | 方正证券：罗俊俞；方正医药：高瑛桥；中信证券：沈睦钧；光 | | 大医药：吴佳青、张杰；广发证券：王少喆、陈明；国海证券： | | 李明；国金医药：徐雨涵；国联证券：安柯；国泰君安证券：赵 | | 峻峰；国信医药：张超；国信证券：何平；华泰证券：杨昌源、 | | 高鹏；华西证券：程仲瑶；华鑫证券：胡博新；开源医药：古意 | ...

Business Focus and Strategy - The company reported a significant shift in its business focus towards ophthalmology services, transitioning from steel structure and clean energy sectors[17]. - The company is actively pursuing mergers and acquisitions to facilitate its strategic transformation in the healthcare sector[17]. - The company has established a dual-driven business model focusing on both steel structure and clean energy, with a recent pivot towards healthcare[16]. - The company plans to continue its market expansion and product development strategies to improve future performance[28]. - The company plans to accelerate the integration of auxiliary industries while concentrating resources on expanding its ophthalmology medical business over the next three years[91]. - The strategic focus includes regional development in key urban clusters such as the Yangtze River Delta and the Beijing-Tianjin-Hebei region, with a "1+6+N" model for expansion[91]. - The company aims to optimize its ophthalmology business structure by focusing on cataracts and fundus diseases, while also developing refractive surgery and other eye care services[91]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its service capabilities[120]. Financial Performance - The company's operating revenue for 2022 was ¥767,444,605.07, a decrease of 26.52% compared to ¥1,044,476,897.11 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥42,668,661.60, reflecting a significant decline of 311.82% from ¥78,217,640.10 in 2021[20]. - The net cash flow from operating activities decreased by 14.48% to ¥124,329,575.96 in 2022, down from ¥145,374,912.47 in 2021[20]. - The basic earnings per share for 2022 was -0.15 yuan, a drop of 314.29% compared to 0.09 yuan in 2021[20]. - Total assets at the end of 2022 were ¥1,557,450,440.86, a decrease of 14.84% from ¥1,834,597,029.60 at the end of 2021[20]. - The company reported a total of ¥212,850,504.77 in non-recurring gains and losses for 2022, compared to ¥107,518,359.13 in 2021[26]. - The company experienced a negative net profit attributable to shareholders in the first and second quarters of 2022, with losses of ¥36,074,792.53 and ¥27,602,037.33 respectively[24]. - The company reported a significant increase in operational costs, impacting overall profitability for the year[119]. Market and Industry Insights - The total number of eye disease patients in China exceeds 1 billion, with myopia and dry eye patients accounting for over 900 million, representing more than 65% of the population[29]. - The ophthalmology service market in China reached 103.7 billion RMB in 2019, with a CAGR of 20% from 2015 to 2019, and is projected to grow to 252.2 billion RMB by 2025, with a CAGR of 17.5%[29]. - The refractive surgery market in China was valued at 18.1 billion RMB in 2019, with a CAGR of 32.3% from 2015 to 2019, and is expected to reach 72.5 billion RMB by 2025, with a CAGR of 28.4%[30]. - The medical optometry market in China reached 22.8 billion RMB in 2019, with a CAGR of 26.2% from 2015 to 2019, and is projected to grow to 50.03 billion RMB by 2025, with a CAGR of 14.6%[31]. - National policies emphasize the importance of eye health, providing strong support for the development of the ophthalmology industry[33]. Operational Developments - The company operates 14 specialized ophthalmology hospitals and 2 optometry clinics across 10 major cities in China, focusing on comprehensive eye care services[35]. - The company has established a national chain network of ophthalmology hospitals, all of which are designated medical insurance institutions, enhancing accessibility for patients[36]. - The company has established a "dual center" for eye diseases, enhancing its research capabilities and academic standing in the ophthalmology field[41]. - The company actively collaborates with renowned institutions and experts to promote medical education and research, addressing the shortage of ophthalmology talent in China[41]. - The company has introduced advanced medical equipment, including the Zeiss VisuMax and Alcon LenSx systems, to provide diverse refractive solutions[44]. - The company has established a comprehensive medical quality management system, focusing on patient safety and service quality[49]. - The company has launched a new telemedicine platform, which is expected to increase patient engagement by 30%[129]. Governance and Compliance - The board has decided not to distribute cash dividends or issue bonus shares for the year[3]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and independent business operation[112]. - The board of directors consists of 9 members, including 3 independent directors, and has held 10 meetings throughout the year to ensure compliance with legal and regulatory requirements[109]. - The company has implemented a stock incentive plan and partner program to strengthen talent motivation and enhance corporate culture[103]. - The independent directors have confirmed compliance with all regulatory requirements, ensuring governance standards are met[127]. - The company has not faced any penalties from regulatory bodies, maintaining a clean compliance record[124]. Talent and Human Resources - The company has implemented a competitive compensation system and a restricted stock incentive plan to stabilize its talent pool[45]. - The company has strengthened its talent acquisition strategy, attracting renowned ophthalmology experts to enhance its medical team[43]. - The company has established a talent reserve mechanism combining "internal training + external introduction" to enhance its talent cultivation system and provide competitive compensation and development platforms for core management personnel[103]. - The company plans to continue its training programs, focusing on enhancing employees' professional and practical skills[166]. - The total number of employees at the end of the reporting period was 1,559, with 1,995 employees receiving salaries[163]. Research and Development - The company has identified accounting errors related to goodwill impairment testing, leading to restatements of previous financial reports[20]. - The company's research and development expenses dropped significantly by 78.39% to ¥855,676.89 due to a decrease in overall revenue and reduced investment in R&D projects[68]. - The company is investing in new product development, including advanced eye care technologies, with an allocated budget of 50 million RMB for R&D[129]. - The company has initiated a collaborative research and education program, establishing clinical research centers to enhance its academic capabilities[50]. Social Responsibility - The company continues to innovate in its long-term incentive mechanisms to stabilize its talent pool and enhance entrepreneurial motivation[54]. - The company established a special fund for children's eye health, focusing on treatment assistance for economically disadvantaged children with eye diseases[55]. - The company is committed to social responsibility by engaging in public welfare activities aimed at improving national eye health[100]. - The company provided over 1,000 job opportunities across various regions, contributing to local economic development and poverty alleviation efforts[188]. - The company actively participated in pandemic prevention and control efforts, contributing to vaccination and testing initiatives[187].

Financial Performance - The company's operating revenue for Q1 2023 was ¥216,369,656.47, representing a 16.23% increase compared to ¥186,164,288.40 in the same period last year[5]. - The net loss attributable to shareholders decreased to ¥7,849,394.18, a 78.24% improvement from a loss of ¥36,074,792.53 in the previous year[5]. - The company reported a basic earnings per share of -¥0.02, an improvement of 71.43% from -¥0.07 in the same period last year[5]. - The net loss for the quarter was CNY 7,320,471.91, an improvement from a net loss of CNY 35,990,985.53 in the same period last year, representing a reduction of approximately 79.7%[17]. - The company reported a basic and diluted earnings per share of CNY -0.02, an improvement from CNY -0.07 in the previous period[17]. Cash Flow - The net cash flow from operating activities increased significantly by 271.59%, reaching ¥2,394,751.79 compared to ¥644,464.97 in Q1 2022[10]. - Cash flow from operating activities generated a net inflow of CNY 2,394,751.79, compared to CNY 644,464.97 in the previous period, showing a significant increase[18]. - The net cash flow from financing activities increased by 35.94% to ¥21,502,794.03, compared to ¥15,817,915.33 in Q1 2022, primarily due to increased bank loans[10]. - Cash flow from financing activities yielded a net inflow of CNY 21,502,794.03, up from CNY 15,817,915.33 in the previous period, indicating a growth of 36.5%[19]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,543,863,988.42, a slight decrease of 0.87% from ¥1,557,450,440.86 at the end of the previous year[5]. - Total current assets increased to ¥283,785,069.80 from ¥269,494,229.50 at the beginning of the year, a growth of approximately 5.8%[13]. - Total liabilities decreased slightly to ¥1,276,026,021.73 from ¥1,282,673,217.12, a reduction of approximately 0.5%[15]. - Non-current assets totaled ¥1,260,078,918.62, down from ¥1,287,956,211.36, a decrease of approximately 2.1%[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 56,600[11]. - The largest shareholder, Guangzheng Investment Co., holds 25.06% of shares, totaling 129,168,708 shares[11]. - The company has no known related party relationships or concerted action among the top ten shareholders[11]. Operating Costs and Income - Total operating costs amounted to CNY 222,317,216.45, slightly up from CNY 221,611,773.81, indicating a marginal increase of 0.3%[16]. - The company recorded a significant increase in other operating income, which rose by 642.78% to ¥558,983.06 from ¥75,255.30 in the previous year[9]. - The company reported a 939.97% increase in asset disposal income, amounting to ¥395,516.75 compared to ¥38,031.61 in the previous year[9]. Investment and Impairment - The company experienced a credit impairment loss of CNY 33,777.49, a significant recovery from a loss of CNY -193,244.94 in the previous period[17]. - The company recorded an investment loss of CNY -1,220,611.38, worsening from a loss of CNY -543,696.86 in the previous period[16]. - The company experienced a 100% decrease in research and development expenses, which were reported as ¥0.00 compared to ¥309,035.23 in the previous year[9].

光正眼科医院集团股份有限公司 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（星期五）15：00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注 的问题进行回答。 欢迎广大投资者积极参与。 特此公告。 光正眼科医院集团股份有限公司董事会 证券代码：002524 证券简称：光正眼科 公告编号：2023-030 光正眼科医院集团股份有限公司 关于举办 2022 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）将于 2023 年 5 月 12 日（星期五）下午 15:00—17:00，举办 2022 年年度报告网上说明会，与广大股 东和投资者对公司发展战略、经营情况等进行沟通和交流。本次年度业绩说明会 将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （h ...

Group 1: Business Overview - Guangzheng Group primarily develops urban gas, vehicle natural gas, and industrial natural gas supply for customers [3] - The industrial demand is weak, while vehicle gas growth remains steady, expected to be the main development direction in the future [3] - The company aims to enhance urban gas development and increase efforts in gasification in southern Xinjiang [3] Group 2: Impact of Natural Gas Price Increase - Despite the rise in natural gas prices, the gross margin for vehicle gas may still be maintained [3] - The focus will be on developing vehicle natural gas with strong capacity to bear costs and enhancing resource acquisition at key stations [3] - The goal is to complete the construction targets for gas stations this year [3] Group 3: Strategic Direction - Due to the increase in natural gas prices, the company plans to consider extending its operations towards the entire industry chain to ensure profitability and stability [3]

证券代码：002524 证券简称：光正集团 光正集团股份有限公司投资者关系活动记录表 编号： | --- | --- | --- | |------------------------------|-------------------------|------------------------------------------------------------| | | | | | 投 资 者 关 | √ 特定对象调研 | □ 分析师会议 | | 系 活 动 类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参 与 单 位 | | 德意志银行：佟江桥、郑振东；博时基金：张溪风、行健资产管理 | | 名 称 及 人 员姓名 | 公司：石冉 | | | 时间 | 2014 年 7 月 29 | 日星期二早晨 10:00-11:30 | | 地点 | | 阿图什重工业园区压缩母站，光正燃气有限公司办公室 | | 上 市 公 司 接 待 人 员 姓名 | | 调度中心主任：吕富 ...

Group 1: Company Overview and Structure - Guangzheng Group has a strategic focus on the ophthalmology sector, with a significant partnership with New Vision Eye Hospital, holding 51% of its shares [5] - The company aims to enhance its operational capabilities and maintain a strong management team to support growth [5][6] - Guangzheng Group is undergoing a transformation to focus solely on ophthalmology, having already divested from its energy sector [7] Group 2: Market Position and Growth Strategy - The ophthalmology market in China is projected to reach a capacity of 160 billion yuan by 2021, with private sector market share at approximately 30% [6] - New Vision Eye Hospital plans to expand its operations in key regions such as Shanghai, Shandong, and Southwest China, while also considering new locations in Beijing and Shenzhen [5][6] - The company aims to leverage its experience in Shanghai to replicate success in other regions, maintaining a unified brand management approach [6][9] Group 3: Business Operations and Services - The primary focus of New Vision's business is on cataract surgeries, which are in high demand due to the aging population in China, with 10.8% of the population over 65 years old [6] - The company is also expanding into refractive and vision care services, responding to market demands and government policies on myopia prevention [4][6] - New Vision's strategic goal is to achieve stable growth in cataract services while enhancing the quality of refractive and vision care services [6][12] Group 4: Financial Performance and Projections - The company anticipates a decline in cataract service revenue due to strategic adjustments, but expects growth in refractive and vision care services to compensate [12] - New Vision's revenue structure is shifting, with a significant increase in non-insured service income [12] - The company is committed to achieving its annual performance targets despite fluctuations in service demand [12] Group 5: Human Resources and Management - Guangzheng Group has implemented an equity incentive plan for its ophthalmology staff to enhance motivation and retention [9] - The company is focused on attracting and training skilled ophthalmologists through various channels, including partnerships with educational institutions [13] - New Vision's management emphasizes the importance of maintaining high-quality patient care and building trust with patients as a core operational principle [9][13]